Imophoron
Imophoron is a Bristol, UK-based pre-clinical biotechnology company developing ADDomer(TM), a proprietary next-generation vaccine platform currently applied to RSV, Chikungunya, and COVID-19 indications for future healthcare and public-health customers.
- Company typePrivate
- Founded2017
- HeadquartersBristol, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Imophoron firmographics
Firmographics- Name
- Imophoron
- Legal name
- Imophoron
- Website
- https://imophoron.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Imophoron is a Bristol, UK-based pre-clinical biotechnology company developing ADDomer(TM), a proprietary next-generation vaccine platform currently applied to RSV, Chikungunya, and COVID-19 indications for future healthcare and public-health customers.
- Ownership category
- akta.pro rank
Imophoron industry classification
Industry- Product category
- Vaccine Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Travel & Tropical Disease Vaccines (HLAIAEAE)
Keywords
Where Imophoron is headquartered
LocationHeadquarters
- HQ city
- Bristol
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Imophoron business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Imophoron product offering
Product offeringCore offering
Imophoron develops a proprietary vaccine platform (ADDomer™) for rapid-response vaccine development against viral pathogens. The company is advancing pre-clinical vaccines targeting respiratory syncytial virus (RSV), Chikungunya virus, and SARS-CoV-2 (COVID-19), focusing on underserved and emerging infectious diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- RSV Vaccine
- Chikungunya Vaccine
- COVID-19 Vaccine
Companies that use Imophoron
Customer profileSegments1 record
Ideal customer profiles1 record
Imophoron technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Imophoron partnerships and signals
Strategic signalScale indicators1 record
Imophoron competitors and assessment
Company assessmentDirect peers
- Valneva: European-headquartered specialty vaccine company developing and commercializing travel/tropical-disease vaccines including the first approved Chikungunya vaccine (Ixchiq). Comparable to Imophoron because both target Chikungunya with next-generation vaccine platforms and focus on underserved infectious-disease indications rather than mass-market primary-care vaccines.
- Emergex Vaccines: UK-based pre-clinical vaccine developer with a synthetic nanopeptide platform (T-cell primed set-point vaccines) targeting infectious diseases including viral pathogens. Comparable to Imophoron as both are UK early-stage platform companies advancing non-mRNA novel vaccine modalities through pre-clinical stages toward infectious-disease targets.
- SpyBiotech: Oxford-originated vaccine platform company using a proprietary protein 'plug' display technology to create virus-like particles, spun out from the University of Oxford. Highly comparable to Imophoron as a UK VLP-based infectious-disease platform biotech that has attracted major-pharma partnership interest.
- ExpreS2ion Biotechnologies: Clinical-stage European biotech developing non-mRNA viral-vector and VLP-based infectious-disease vaccines using an insect-cell protein production platform. Comparable to Imophoron because both are small, platform-driven vaccine developers targeting infectious-disease indications using non-mRNA novel modalities.
- VBI Vaccines: Small-cap vaccine platform company developing enveloped VLP (eVLP) technology targeting infectious diseases including RSV and coronaviruses. Comparable to Imophoron as a similarly-sized, platform-based vaccine developer focused on VLP modalities and overlapping disease targets.
Broad incumbents
- Novavax: Public recombinant-protein nanoparticle vaccine company with approved COVID-19 vaccine (Nuvaxovid) and clinical-stage RSV program. Comparable to Imophoron because it operates a protein-subunit/nanoparticle vaccine platform and competes head-to-head in the COVID-19 and RSV target indications.
- Bavarian Nordic: Established vaccine company with approved smallpox/mpox and chikungunya vaccine (Vimkunya) products. Comparable to Imophoron as a mid-sized specialty vaccine incumbent with direct Chikungunya overlap and a focus on public-health/emerging infectious-disease markets.
- Moderna: Large mRNA vaccine company with approved COVID-19 vaccine, RSV vaccine (mResvia), and broad infectious-disease pipeline. Comparable to Imophoron because it competes in the same RSV and COVID-19 indication spaces and defines the alternative 'rapid-response' pandemic-preparedness vaccine-platform business model that Imophoron's ADDomer platform is attempting to emulate.
- CureVac: European mRNA vaccine platform company with broad infectious-disease pipeline and a focus on rapid-response pandemic vaccines. Comparable to Imophoron because it pursues a similar 'platform for rapid vaccine deployment' commercial thesis against infectious diseases.
Emerging players
- AdaptVac: Danish VLP vaccine platform company (cVLP technology) spun out from the University of Copenhagen, with programs in RSV and other infectious diseases. Comparable to Imophoron as a small-cap VLP platform developer pursuing overlapping disease targets including RSV.
Market position
Customer concentration
Imophoron social profiles
Digital presenceImophoron financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imophoron leadership team
Management profileNumber of profiles
Profiles2 records
Imophoron funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imophoron M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imophoron
What does Imophoron do?
Imophoron develops a proprietary vaccine platform (ADDomer™) for rapid-response vaccine development against viral pathogens. The company is advancing pre-clinical vaccines targeting respiratory syncytial virus (RSV), Chikungunya virus, and SARS-CoV-2 (COVID-19), focusing on underserved and emerging infectious diseases.
Is Imophoron a public or private company?
Imophoron is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imophoron founded?
Imophoron was founded in 2017. It employs 1 to 10 people.
Where is Imophoron based?
Imophoron is headquartered in Bristol, United Kingdom, in the Europe region.
Who are Imophoron's main competitors?
Direct peers on record are Valneva, Emergex Vaccines, SpyBiotech, ExpreS2ion Biotechnologies and VBI Vaccines. Broad incumbents are Novavax, Bavarian Nordic, Moderna and CureVac. AdaptVac is listed as an emerging player.
Does Imophoron have an API?
No public API is recorded for Imophoron.
What industry is Imophoron in?
Imophoron's product category is Vaccine Development. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325412 and its SIC code is 2834.